Published in Neuron on August 05, 2004
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med (2005) 2.43
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J (2008) 2.43
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol (2010) 1.80
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Altered lipid metabolism in brain injury and disorders. Subcell Biochem (2008) 1.69
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 1.55
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med (2008) 1.46
Alzheimer's disease: synapses gone cold. Mol Neurodegener (2011) 1.43
Immunotherapy for Alzheimer's disease. J Intern Med (2011) 1.43
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain (2008) 1.42
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.37
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol (2013) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell (2013) 1.24
Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2005) 1.24
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
Role of Lipids in Brain Injury and Diseases. Future Lipidol (2007) 1.23
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Transgenic models of Alzheimer's disease: learning from animals. NeuroRx (2005) 1.21
Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol (2008) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron (2014) 1.19
Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis (2010) 1.19
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One (2010) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
A novel calcium-binding protein is associated with tau proteins in tauopathy. J Neurochem (2008) 1.16
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging (2008) 1.14
β-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging (2009) 1.13
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum Mol Genet (2011) 1.12
Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem (2011) 1.12
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell (2014) 1.11
A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum Mol Genet (2011) 1.10
Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med (2010) 1.09
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol Neurodegener (2012) 1.09
The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med (2015) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease. Front Aging Neurosci (2010) 1.07
Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol (2006) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther (2010) 1.06
The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 1.06
Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res (2009) 1.05
Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther (2014) 1.05
Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. Cell Adh Migr (2009) 1.05
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med (2008) 1.04
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease. N Engl J Med (2010) 13.13
A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92
Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84
Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82
Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52
Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci (2007) 1.47
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci (2007) 1.46
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem (2008) 1.36
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis (2007) 1.30
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest (2004) 1.29
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem (2007) 1.22
Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci (2007) 1.22
Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci (2006) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci (2011) 1.18
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One (2010) 1.17
Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci (2003) 1.17
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris (2006) 1.11
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11
Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging (2012) 1.10
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol (2010) 1.05
Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther (2014) 1.05
Spatial frequency domain imaging of intrinsic optical property contrast in a mouse model of Alzheimer's disease. Ann Biomed Eng (2011) 1.05
Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci (2004) 1.03
Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis (2003) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging (2007) 1.02
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci (2012) 1.01
Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem (2011) 1.01
Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol (2012) 1.01
Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res (2010) 1.00
Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci (2007) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Amyloid beta-peptide: the inside story. Curr Alzheimer Res (2004) 0.99
Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann N Y Acad Sci (2010) 0.99
Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging (2005) 0.99
A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98
Hippocampal brain-derived neurotrophic factor gene regulation by exercise and the medial septum. J Neurosci Res (2002) 0.97